$KRYS
Krystal Biotech, Inc. Stock $krys

$krys Overview Financials Valuation SEC Filings Company Website

2021 Form 10-K Financial Statement

#000171127922000004 Filed on February 28, 2022

Income Statement

Concept	2021	2020 Q4	2020 Q1
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$40.39M	$4.750M	$2.420M
YoY Change	168.2%	162.43%	58.17%
% of Gross Profit
Research & Development	$27.88M	$5.670M	$3.525M
YoY Change	55.46%	30.34%	11.3%
% of Gross Profit
Depreciation & Amortization	$2.769M	$490.0K	$335.0K
YoY Change	49.59%	44.12%	153.79%
% of Gross Profit
Operating Expenses	$68.28M	$10.42M	$5.946M
YoY Change	106.9%	69.43%	87.75%
Operating Profit	-$68.28M		-$5.946M
YoY Change	106.9%
Interest Expense	$1.492M	$40.00K	$0.00
YoY Change		-95.0%	-100.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$69.57M	-$10.38M	-$5.340M
YoY Change	116.26%	93.66%	29.93%
Income Tax	$0.00
% Of Pretax Income
Net Earnings	-$69.57M	-$10.38M	-$5.341M
YoY Change	116.28%	93.66%	29.92%
Net Earnings / Revenue
Basic Earnings Per Share	-$3.13
Diluted Earnings Per Share	-$3.13	-$526.4K	-$307.6K
COMMON SHARES
Basic Shares Outstanding	22.20M shares	19.71M shares	17.36M
Diluted Shares Outstanding	22.20M shares

Balance Sheet

Concept	2021	2020 Q4	2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$438.1M	$271.3M	$186.7M
YoY Change	61.48%	40.05%	75.14%
Cash & Equivalents	$341.2M	$268.3M	$180.2M
Short-Term Investments	$96.85M	$2.993M	$6.500M
Other Short-Term Assets	$4.171M	$3.800M	$1.600M
YoY Change	9.76%	72.73%	23.08%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$442.3M	$275.1M	$188.3M
YoY Change	60.77%	40.42%	74.51%
LONG-TERM ASSETS
Property, Plant & Equipment	$119.6M	$30.88M	$12.90M
YoY Change	249.66%	264.32%	74.32%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$64.37M	$0.00	$0.00
YoY Change		-100.0%
Other Assets	$74.00K	$1.612M	$3.900M
YoY Change	-95.38%	10.26%	757.14%
Total Long-Term Assets	$184.0M	$35.79M	$16.80M
YoY Change	415.48%	172.28%	115.27%
TOTAL ASSETS
Total Short-Term Assets	$442.3M	$275.1M	$188.3M
Total Long-Term Assets	$184.0M	$35.79M	$16.80M
Total Assets	$626.3M	$310.8M	$205.1M
YoY Change	101.51%	48.71%	77.26%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$8.398M	$2.105M	$600.0K
YoY Change	299.9%	106.17%	-46.71%
Accrued Expenses	$17.17M	$5.700M	$3.200M
YoY Change	201.19%	128.0%	52.38%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$25.74M	$15.45M	$4.100M
YoY Change	66.04%	364.44%	26.47%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$6.983M	$3.300M	$2.700M
YoY Change	111.61%	17.86%	-10.0%
Total Long-Term Liabilities	$6.983M	$3.300M	$2.700M
YoY Change	111.61%	17.86%	-10.0%
TOTAL LIABILITIES
Total Short-Term Liabilities	$25.74M	$15.45M	$4.100M
Total Long-Term Liabilities	$6.983M	$3.300M	$2.700M
Total Liabilities	$32.72M	$18.76M	$6.800M
YoY Change	74.04%	207.09%	9.36%
SHAREHOLDERS EQUITY
Retained Earnings		-$71.21M
YoY Change		82.38%
Common Stock		$0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$593.6M	$292.1M	$198.4M
YoY Change
Total Liabilities & Shareholders Equity	$626.3M	$310.8M	$205.1M
YoY Change	101.51%	48.71%	77.26%

Cashflow Statement

Concept	2021	2020 Q4	2020 Q1
OPERATING ACTIVITIES
Net Income	-$69.57M	-$10.38M	-$5.341M
YoY Change	116.28%	93.66%	29.92%
Depreciation, Depletion And Amortization	$2.769M	$490.0K	$335.0K
YoY Change	49.59%	44.12%	153.79%
Cash From Operating Activities	-$47.94M	-$8.020M	-$6.227M
YoY Change	83.79%	14.57%	93.69%
INVESTING ACTIVITIES
Capital Expenditures	$68.34M	-$7.200M	$1.508M
YoY Change	360.39%	215.79%	-11.66%
Acquisitions
YoY Change
Other Investing Activities	-$158.4M	$990.0K	$200.0K
YoY Change	-4428.8%	-41.42%	-125.64%
Cash From Investing Activities	-$226.8M	-$6.220M	-$1.305M
YoY Change	1928.17%	954.24%	-47.42%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$355.6M		$243.0K
YoY Change	201.35%		507.5%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$347.7M	140.0K	$243.0K
YoY Change	194.6%	-53.33%	507.5%
NET CHANGE
Cash From Operating Activities	-$47.94M	-8.020M	-$6.227M
Cash From Investing Activities	-$226.8M	-6.220M	-$1.305M
Cash From Financing Activities	$347.7M	140.0K	$243.0K
Net Change In Cash	$72.98M	-14.10M	-$7.289M
YoY Change	-9.63%	93.42%	28.85%
FREE CASH FLOW
Cash From Operating Activities	-$47.94M	-$8.020M	-$6.227M
Capital Expenditures	$68.34M	-$7.200M	$1.508M
Free Cash Flow	-$116.3M	-$820.0K	-$7.735M
YoY Change	184.11%	-82.63%	57.15%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021	dei	Amendment Flag AmendmentFlag	false
CY2021	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021	dei	Entity Central Index Key EntityCentralIndexKey	0001711279
CY2021	dei	Document Type DocumentType	10-K
CY2021	dei	Document Annual Report DocumentAnnualReport	true
CY2021	dei	Document Period End Date DocumentPeriodEndDate	2021-12-31
CY2021	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021	dei	Document Transition Report DocumentTransitionReport	false
CY2021	dei	Entity File Number EntityFileNumber	001-38210
CY2021	dei	Entity Registrant Name EntityRegistrantName	Krystal Biotech, Inc.
CY2021	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	82-1080209
CY2021	dei	Entity Address Address Line1 EntityAddressAddressLine1	2100 Wharton Street
CY2021	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 701
CY2021	dei	Entity Address City Or Town EntityAddressCityOrTown	Pittsburgh
CY2021	dei	Entity Address State Or Province EntityAddressStateOrProvince	PA
CY2021	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	15203
CY2021	dei	City Area Code CityAreaCode	412
CY2021	dei	Local Phone Number LocalPhoneNumber	586-5830
CY2021	dei	Security12b Title Security12bTitle	Common Stock
CY2021	dei	Trading Symbol TradingSymbol	KRYS
CY2021	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2021	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2021	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2021	dei	Entity Small Business EntitySmallBusiness	true
CY2021	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2021	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2021	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	dei	Entity Public Float EntityPublicFloat	1200000000	USD
CY2022Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	25208085	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	25207985	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	25207985	shares
CY2021	dei	Auditor Firm AuditorFirmId	199
CY2021	dei	Auditor Name AuditorName	Mayer Hoffman McCann P.C.
CY2021	dei	Auditor Location AuditorLocation	San Diego, California
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	341246000	USD
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	268269000	USD
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	96850000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	2993000	USD
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4171000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3796000	USD
CY2021Q4	us-gaap	Assets Current AssetsCurrent	442267000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	275058000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	112355000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	30876000	USD
CY2021Q4	us-gaap	Long Term Investments LongTermInvestments	64371000	USD
CY2020Q4	us-gaap	Long Term Investments LongTermInvestments	0	USD
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	7228000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3298000	USD
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	74000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1612000	USD
CY2021Q4	us-gaap	Assets Assets	626295000	USD
CY2020Q4	us-gaap	Assets Assets	310844000	USD
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	8398000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2105000	USD
CY2021Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	1041000	USD
CY2020Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	638000	USD
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	16297000	USD
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	5109000	USD
CY2021Q4	krys	Build To Suit Lease Liability Current BuildToSuitLeaseLiabilityCurrent	0	USD
CY2020Q4	krys	Build To Suit Lease Liability Current BuildToSuitLeaseLiabilityCurrent	7600000	USD
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	25736000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	15452000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	6983000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3308000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	593576000	USD
CY2021Q4	us-gaap	Liabilities Liabilities	32719000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	18760000	USD
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.00001
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	2061773	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	2061773	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.00001
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	80000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	80000000	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	25207985	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	25207985	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	19714220	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	19714220	shares
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	0	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	0	USD
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	734523000	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	363292000	USD
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-163000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	6000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-140784000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-71214000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	292084000	USD
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	626295000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	310844000	USD
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	27884000	USD
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	17936000	USD
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	40391000	USD
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	15063000	USD
CY2021	us-gaap	Operating Expenses OperatingExpenses	68275000	USD
CY2020	us-gaap	Operating Expenses OperatingExpenses	32999000	USD
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-68275000	USD
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-32999000	USD
CY2021	krys	Interest Income Expense And Other Nonoperating Net InterestIncomeExpenseAndOtherNonoperatingNet	197000	USD
CY2020	krys	Interest Income Expense And Other Nonoperating Net InterestIncomeExpenseAndOtherNonoperatingNet	832000	USD
CY2021	us-gaap	Interest Expense InterestExpense	1492000	USD
CY2020	us-gaap	Interest Expense InterestExpense	0	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-32167000	USD
CY2020	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-4000	USD
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	22196846	shares
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-69739000	USD
CY2020	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-32171000	USD
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.13
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.13
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.71
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.71
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	22196846	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	18787161	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	18787161	shares
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	202914000	USD
CY2020	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	118035000	USD
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3306000	USD
CY2020	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-4000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-32167000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	292084000	USD
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	355628000	USD
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	15603000	USD
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-169000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-69570000	USD
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	593576000	USD
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-69570000	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-32167000	USD
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	2769000	USD
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1851000	USD
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	15319000	USD
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	3272000	USD
CY2021	us-gaap	Gains Losses On Sales Of Assets GainsLossesOnSalesOfAssets	0	USD
CY2020	us-gaap	Gains Losses On Sales Of Assets GainsLossesOnSalesOfAssets	-33000	USD
CY2021	us-gaap	Other Noncash Expense OtherNoncashExpense	1492000	USD
CY2020	us-gaap	Other Noncash Expense OtherNoncashExpense	0	USD
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1145000	USD
CY2020	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1911000	USD
CY2021	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-65000	USD
CY2020	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	934000	USD
CY2021	krys	Increase Decrease In Lease Liability IncreaseDecreaseInLeaseLiability	-285000	USD
CY2020	krys	Increase Decrease In Lease Liability IncreaseDecreaseInLeaseLiability	685000	USD
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	712000	USD
CY2020	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	783000	USD
CY2021	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	2705000	USD
CY2020	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	2305000	USD
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-47938000	USD
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-26083000	USD
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	68336000	USD
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	14843000	USD
CY2021	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	190462000	USD
CY2020	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	3205000	USD
CY2021	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	32028000	USD
CY2020	us-gaap	Proceeds From Sale Maturity And Collection Of Shortterm Investments ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments	6867000	USD
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-226770000	USD
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-11181000	USD
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	355645000	USD
CY2020	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	118019000	USD
CY2021	krys	Payments For Suit Liability PaymentsForSuitLiability	7960000	USD
CY2020	krys	Payments For Suit Liability PaymentsForSuitLiability	0	USD
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	347685000	USD
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	118019000	USD
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	72977000	USD
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	80755000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	268269000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	187514000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	341246000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	268269000	USD
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	15363000	USD
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	9697000	USD
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	4396000	USD
CY2020	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	911000	USD
CY2021	krys	Offering Costs Incurred But Not Yet Paid OfferingCostsIncurredButNotYetPaid	0	USD
CY2020	krys	Offering Costs Incurred But Not Yet Paid OfferingCostsIncurredButNotYetPaid	131000	USD
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-140800000	USD
CY2021Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	438100000	USD
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:6pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts in the consolidated financial statements and accompanying notes. Actual results could materially differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including: expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of the financial statements. Estimates are used in the following areas, including: stock-based compensation expense, accrued expenses, the fair value of financial instruments, the incremental borrowing rate for lease liabilities, construction in progress, and the valuation allowance included in the deferred income tax calculation.</span></div>
CY2021	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	18787161	shares
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.13
CY2021	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<div style="margin-top:12pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Credit Risk and Off-Balance Sheet Risk</span></div><div style="margin-top:6pt;text-indent:29.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Financial instruments that potentially subject the Company to credit risk consist of cash, cash equivalents and investments. The Company’s policy is to invest its cash, cash equivalents and investments in money market funds, certificates of deposit, corporate bonds, commercial paper, government agency securities and various other bank deposit accounts. The counterparties to the agreements relating to the Company’s investments consist of financial institutions of high credit standing. The Company is exposed to credit risk in the event of default by the financial institutions to the extent amounts recorded on the balance sheets are in excess of insured limits. The Company has not experienced any credit losses in such accounts and does not believe it is exposed to any significant credit risk on these funds. The Company has no financial instruments with off-balance sheet risk of loss.</span></div>
CY2021	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0	USD
CY2021Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	USD
CY2020Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	USD
CY2021	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0	USD
CY2020	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0	USD
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-32167000	USD
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	22196846	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	22196846	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	18787161	shares
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	11000	USD
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	180000	USD
CY2020Q4	krys	Cash Cash Equivalents And Debt Securities Available For Sale Amortized Cost CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost	271255000	USD
CY2021Q4	krys	Cash Cash Equivalents And Debt Securities Available For Sale CashCashEquivalentsAndDebtSecuritiesAvailableForSale	502467000	USD
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.13
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.71
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.71
CY2021Q4	krys	Cash Cash Equivalents And Debt Securities Available For Sale Amortized Cost CashCashEquivalentsAndDebtSecuritiesAvailableForSaleAmortizedCost	502636000	USD
CY2020Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	7000	USD
CY2020Q4	krys	Cash Cash Equivalents And Debt Securities Available For Sale CashCashEquivalentsAndDebtSecuritiesAvailableForSale	271262000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	116569000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	33244000	USD
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4214000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	2368000	USD
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	112355000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	30876000	USD
CY2021	us-gaap	Depreciation Depreciation	1800000	USD
CY2020	us-gaap	Depreciation Depreciation	1500000	USD
CY2021Q4	krys	Accrued Preclinical And Clinical Expenses AccruedPreclinicalAndClinicalExpenses	1602000	USD
CY2020Q4	krys	Accrued Preclinical And Clinical Expenses AccruedPreclinicalAndClinicalExpenses	1179000	USD
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2011000	USD
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1198000	USD
CY2021Q4	krys	Accrued Payroll And Benefits AccruedPayrollAndBenefits	2882000	USD
CY2020Q4	krys	Accrued Payroll And Benefits AccruedPayrollAndBenefits	1486000	USD
CY2021Q4	us-gaap	Accrued Income Taxes AccruedIncomeTaxes	83000	USD
CY2020Q4	us-gaap	Accrued Income Taxes AccruedIncomeTaxes	40000	USD
CY2021Q4	krys	Accrued Construction In Progress And Laboratory Equipment AccruedConstructionInProgressAndLaboratoryEquipment	9606000	USD
CY2020Q4	krys	Accrued Construction In Progress And Laboratory Equipment AccruedConstructionInProgressAndLaboratoryEquipment	1049000	USD
CY2021Q4	krys	Accrued Financing Fees Current AccruedFinancingFeesCurrent	26000	USD
CY2020Q4	krys	Accrued Financing Fees Current AccruedFinancingFeesCurrent	131000	USD
CY2021Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	87000	USD
CY2020Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	26000	USD
CY2021Q4	krys	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	16297000	USD
CY2020Q4	krys	Accrued Expenses And Other Current Liabilities AccruedExpensesAndOtherCurrentLiabilities	5109000	USD
CY2020Q1	krys	Payment To Escrow For Reducing Lease Rentals PaymentToEscrowForReducingLeaseRentals	2400000	USD
CY2020Q4	krys	Purchase Price Of Potential Building Purchase PurchasePriceOfPotentialBuildingPurchase	9400000	USD
CY2020Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	10000000	USD
CY2020Q1	us-gaap	Construction In Progress Gross ConstructionInProgressGross	10000000	USD
CY2020Q1	krys	Payment To Escrow For Reducing Lease Rentals PaymentToEscrowForReducingLeaseRentals	2400000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Term Of Contract LesseeOperatingLeaseTermOfContract	P3Y
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	7228000	USD
CY2020	us-gaap	Variable Lease Cost VariableLeaseCost	57000	USD
CY2021	krys	Cumulative Escalation Clause Term CumulativeEscalationClauseTerm	P5Y
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P14Y4M24D
CY2020Q4	krys	Purchase Price Of Potential Building Purchase PurchasePriceOfPotentialBuildingPurchase	9400000	USD
CY2020Q4	us-gaap	Escrow Deposit EscrowDeposit	1500000	USD
CY2021	krys	Lessor Operating Lease Liability Annual Lease Payments LessorOperatingLeaseLiabilityAnnualLeasePayments	82000	USD
CY2021	krys	Cumulative Escalation Clause Percent CumulativeEscalationClausePercent	0.10
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1094000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	1114000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1135000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	1162000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Five LesseeOperatingLeaseLiabilityPaymentsDueYearFive	1186000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	11600000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	17291000	USD
CY2021Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	9267000	USD
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	8024000	USD
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3298000	USD
CY2021Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	1041000	USD
CY2020Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	638000	USD
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	6983000	USD
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3308000	USD
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	8024000	USD
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	3946000	USD
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P16Y4M24D
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.095
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.094
CY2021	us-gaap	Operating Lease Expense OperatingLeaseExpense	1300000	USD
CY2020	us-gaap	Operating Lease Expense OperatingLeaseExpense	767000	USD
CY2021	us-gaap	Variable Lease Cost VariableLeaseCost	160000	USD
CY2021	krys	Purchase Price Of Potential Building Purchase PurchasePriceOfPotentialBuildingPurchase	24700000	USD
CY2021Q3	krys	Loss Contingency Guaranteed Maximum Price To Be Paid LossContingencyGuaranteedMaximumPriceToBePaid	80800000	USD
CY2021	krys	Loss Contingency Receivable Received Amount LossContingencyReceivableReceivedAmount	1600000	USD
CY2021	us-gaap	Loss Contingency Related Receivable Carrying Value Additions LossContingencyRelatedReceivableCarryingValueAdditions	560000	USD
CY2021Q4	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	227000	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Stock Issued Issuance Costs AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts	198000	USD
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod	P10Y
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	420766	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	17.71
CY2019	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y4M24D
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	15859000	USD
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	891250	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	47.29
CY2020	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	84285	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	10.45
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	374117	shares
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	38.24
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	0	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	0
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	853614	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	40.31
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	16804000	USD
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1422450	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	66.88
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	54260	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	38.12
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	175750	shares
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	61.35
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod	2875	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice	75.82
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2043179	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	57.00
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	31331000	USD
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	307250	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	33.00
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P7Y6M
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	11354000	USD
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	13700000	USD
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	USD
CY2021	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	0	USD
CY2021	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	0	USD
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	13669000	USD
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3272000	USD
CY2021	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	284000	USD
CY2020	us-gaap	Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount	34000	USD
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3300000	USD
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-14578000	USD
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-6752000	USD
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	20689000	USD
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	11112000	USD
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-5436000	USD
CY2020	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-2632000	USD
CY2021	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	1295000	USD
CY2020	us-gaap	Income Tax Reconciliation Tax Credits IncomeTaxReconciliationTaxCredits	887000	USD
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	675000	USD
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	-216000	USD
CY2021	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	-55000	USD
CY2020	us-gaap	Income Tax Reconciliation Other Reconciling Items IncomeTaxReconciliationOtherReconcilingItems	-625000	USD
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	USD
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	33170000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	19189000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	3906000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	664000	USD
CY2021Q4	krys	Deferred Tax Assets Build To Suit Lease Liability DeferredTaxAssetsBuildToSuitLeaseLiability	0	USD
CY2020Q4	krys	Deferred Tax Assets Build To Suit Lease Liability DeferredTaxAssetsBuildToSuitLeaseLiability	2893000	USD
CY2021Q4	krys	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	2344000	USD
CY2020Q4	krys	Deferred Tax Assets Lease Liability DeferredTaxAssetsLeaseLiability	1142000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	679000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	123000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	817000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Accrued Liabilities DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities	46000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	884000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	0	USD
CY2021Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	3607000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	2311000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	45407000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	26368000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	42732000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	22043000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	2675000	USD
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	4325000	USD
CY2021Q4	krys	Deferred Tax Liabilities Capitalized Construction Costs DeferredTaxLiabilitiesCapitalizedConstructionCosts	0	USD
CY2020Q4	krys	Deferred Tax Liabilities Capitalized Construction Costs DeferredTaxLiabilitiesCapitalizedConstructionCosts	2893000	USD
CY2021Q4	krys	Deferred Tax Liabilities Right Of Use Asset DeferredTaxLiabilitiesRightOfUseAsset	2111000	USD
CY2020Q4	krys	Deferred Tax Liabilities Right Of Use Asset DeferredTaxLiabilitiesRightOfUseAsset	954000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	613000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	476000	USD
CY2021Q4	krys	Deferred Tax Liabilities Unrealized Loss On Marketable Securities DeferredTaxLiabilitiesUnrealizedLossOnMarketableSecurities	-49000	USD
CY2020Q4	krys	Deferred Tax Liabilities Unrealized Loss On Marketable Securities DeferredTaxLiabilitiesUnrealizedLossOnMarketableSecurities	2000	USD
CY2021Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	2675000	USD
CY2020Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	4325000	USD
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2020Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0	USD
CY2021	krys	Ownership Interest Rate Change Over Period OwnershipInterestRateChangeOverPeriod	P3Y

Files In Submission

Name	View Source	Status
0001711279-22-000004-index-headers.html	Edgar Link	pending
0001711279-22-000004-index.html	Edgar Link	pending
0001711279-22-000004.txt	Edgar Link	pending
0001711279-22-000004-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
krys-20211231.htm	Edgar Link	pending
krys-20211231.xsd	Edgar Link	pending
krys-20211231ex1017_sixt.htm	Edgar Link	pending
krys-20211231ex1017_sixt001.jpg	Edgar Link	pending
krys-20211231ex1017_sixt002.jpg	Edgar Link	pending
krys-20211231ex1017_sixt003.jpg	Edgar Link	pending
krys-20211231ex1017_sixt004.jpg	Edgar Link	pending
krys-20211231ex1017_sixt005.jpg	Edgar Link	pending
krys-20211231ex1017_sixt006.jpg	Edgar Link	pending
krys-20211231ex1017_sixt007.jpg	Edgar Link	pending
krys-20211231ex1017_sixt008.jpg	Edgar Link	pending
krys-20211231ex1017_sixt009.jpg	Edgar Link	pending
krys-20211231ex1017_sixt010.jpg	Edgar Link	pending
krys-20211231ex1017_sixt011.jpg	Edgar Link	pending
krys-20211231ex1017_sixt012.jpg	Edgar Link	pending
krys-20211231ex1017_sixt013.jpg	Edgar Link	pending
krys-20211231ex1017_sixt014.jpg	Edgar Link	pending
krys-20211231ex1017_sixt015.jpg	Edgar Link	pending
krys-20211231ex1017_sixt016.jpg	Edgar Link	pending
krys-20211231ex1018_seve.htm	Edgar Link	pending
krys-20211231ex1018_seve001.jpg	Edgar Link	pending
krys-20211231ex1018_seve002.jpg	Edgar Link	pending
krys-20211231ex1018_seve003.jpg	Edgar Link	pending
krys-20211231ex1018_seve004.jpg	Edgar Link	pending
krys-20211231ex1018_seve005.jpg	Edgar Link	pending
krys-20211231ex1018_seve006.jpg	Edgar Link	pending
krys-20211231ex1018_seve007.jpg	Edgar Link	pending
krys-20211231ex1018_seve008.jpg	Edgar Link	pending
krys-20211231ex1018_seve009.jpg	Edgar Link	pending
krys-20211231ex1018_seve010.jpg	Edgar Link	pending
krys-20211231ex1018_seve011.jpg	Edgar Link	pending
krys-20211231ex1018_seve012.jpg	Edgar Link	pending
krys-20211231ex1018_seve013.jpg	Edgar Link	pending
krys-20211231ex1018_seve014.jpg	Edgar Link	pending
krys-20211231ex1018_seve015.jpg	Edgar Link	pending
krys-20211231ex1018_seve016.jpg	Edgar Link	pending
krys-20211231ex1018_seve017.jpg	Edgar Link	pending
krys-20211231ex1019_eigh.htm	Edgar Link	pending
krys-20211231ex1019_eigh001.jpg	Edgar Link	pending
krys-20211231ex1019_eigh002.jpg	Edgar Link	pending
krys-20211231ex1019_eigh003.jpg	Edgar Link	pending
krys-20211231ex1019_eigh004.jpg	Edgar Link	pending
krys-20211231ex1019_eigh005.jpg	Edgar Link	pending
krys-20211231ex1019_eigh006.jpg	Edgar Link	pending
krys-20211231ex1019_eigh007.jpg	Edgar Link	pending
krys-20211231ex1019_eigh008.jpg	Edgar Link	pending
krys-20211231ex1020_nine.htm	Edgar Link	pending
krys-20211231ex1020_nine001.jpg	Edgar Link	pending
krys-20211231ex1020_nine002.jpg	Edgar Link	pending
krys-20211231ex1020_nine003.jpg	Edgar Link	pending
krys-20211231ex1020_nine004.jpg	Edgar Link	pending
krys-20211231ex1020_nine005.jpg	Edgar Link	pending
krys-20211231ex1020_nine006.jpg	Edgar Link	pending
krys-20211231ex1020_nine007.jpg	Edgar Link	pending
krys-20211231ex1020_nine008.jpg	Edgar Link	pending
krys-20211231ex1020_nine009.jpg	Edgar Link	pending
krys-20211231ex1020_nine010.jpg	Edgar Link	pending
krys-20211231ex1020_nine011.jpg	Edgar Link	pending
krys-20211231ex1020_nine012.jpg	Edgar Link	pending
krys-20211231ex1020_nine013.jpg	Edgar Link	pending
krys-20211231ex1020_nine014.jpg	Edgar Link	pending
krys-20211231ex1020_nine015.jpg	Edgar Link	pending
krys-20211231ex1020_nine016.jpg	Edgar Link	pending
krys-20211231ex105_emplo.htm	Edgar Link	pending
krys-20211231ex105_emplo001.jpg	Edgar Link	pending
krys-20211231ex105_emplo002.jpg	Edgar Link	pending
krys-20211231ex105_emplo003.jpg	Edgar Link	pending
krys-20211231ex105_emplo004.jpg	Edgar Link	pending
krys-20211231ex105_emplo005.jpg	Edgar Link	pending
krys-20211231ex105_emplo006.jpg	Edgar Link	pending
krys-20211231ex105_emplo007.jpg	Edgar Link	pending
krys-20211231ex105_emplo008.jpg	Edgar Link	pending
krys-20211231ex106_emplo.htm	Edgar Link	pending
krys-20211231ex106_emplo001.jpg	Edgar Link	pending
krys-20211231ex106_emplo002.jpg	Edgar Link	pending
krys-20211231ex106_emplo003.jpg	Edgar Link	pending
krys-20211231ex106_emplo004.jpg	Edgar Link	pending
krys-20211231ex106_emplo005.jpg	Edgar Link	pending
krys-20211231ex106_emplo006.jpg	Edgar Link	pending
krys-20211231ex106_emplo007.jpg	Edgar Link	pending
krys-20211231ex106_emplo008.jpg	Edgar Link	pending
krys-20211231ex211_subsi.htm	Edgar Link	pending
krys-20211231ex211_subsi001.jpg	Edgar Link	pending
krys-20211231ex231_conse.htm	Edgar Link	pending
krys-20211231ex231_conse001.jpg	Edgar Link	pending
krys-20211231ex311.htm	Edgar Link	pending
krys-20211231ex312.htm	Edgar Link	pending
krys-20211231ex321.htm	Edgar Link	pending
krys-20211231ex322.htm	Edgar Link	pending
krys-20211231_cal.xml	Edgar Link	unprocessable
krys-20211231_def.xml	Edgar Link	unprocessable
krys-20211231_g1.jpg	Edgar Link	pending
krys-20211231_g2.jpg	Edgar Link	pending
krys-20211231_htm.xml	Edgar Link	completed
krys-20211231_lab.xml	Edgar Link	unprocessable
krys-20211231_pre.xml	Edgar Link	unprocessable
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$KRYS
Krystal Biotech, Inc. Stock $krys

2021 Form 10-K Financial Statement

#000171127922000004 Filed on February 28, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$KRYS Krystal Biotech, Inc. Stock $krys

2021 Form 10-K Financial Statement

#000171127922000004 Filed on February 28, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$KRYS
Krystal Biotech, Inc. Stock $krys